-
-
-
-
-
-
-
ARS Pharmaceuticals Inc (SPRY) PT Raised to $30 at Cantor Fitzgerald
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)
-
-
-
-
-
-
-
ARS Pharmaceuticals secures $250 million loan facility for neffy expansion
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)
-
-
-
-
-
-
-
ARS Pharmaceuticals (SPRY) Announces FDA Approval of neffy 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis
-
-
-
-
-
-
-
Cantor Fitzgerald Starts ARS Pharmaceuticals Inc (SPRY) at Overweight
-
-
-
456,970 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

